Modafinil for atypical depression: effects of open-label and double-blind discontinuation treatment.

Published

Journal Article

Atypical depression, with features of hypersomnia, hyperphagia, anergia, and rejection sensitivity, is a common presentation of major depressive disorder. There are few available effective therapies for this disorder. We test modafinil, a novel wake-promoting agent, as monotherapy for atypical depression in a double-blind, placebo-controlled, relapse prevention trial after open-label treatment. We found that modafinil significantly improved atypical depression symptoms during 12 weeks of open-label treatment (mean +/- SD Hamilton Depression Scale (29-item version) score changed from 34 +/- 8.2 at baseline to 9.7 +/- 9.3, P < 0.0001), and that benefits were maintained alike in both the continuation and placebo arms during the double-blind treatment phase (P = 0.92). Modafinil was well tolerated and the drug was associated with significant weight loss compared with placebo (P = 0.01).

Full Text

Duke Authors

Cited Authors

  • Vaishnavi, S; Gadde, K; Alamy, S; Zhang, W; Connor, K; Davidson, JRT

Published Date

  • August 2006

Published In

Volume / Issue

  • 26 / 4

Start / End Page

  • 373 - 378

PubMed ID

  • 16855454

International Standard Serial Number (ISSN)

  • 0271-0749

Digital Object Identifier (DOI)

  • 10.1097/01.jcp.0000227700.263.75.39

Language

  • eng

Conference Location

  • United States